These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1378983)

  • 1. Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin.
    Sargent ER; Williams RD
    Urol Clin North Am; 1992 Aug; 19(3):581-9. PubMed ID: 1378983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins.
    Moltedo B; Faunes F; Haussmann D; De Ioannes P; De Ioannes AE; Puente J; Becker MI
    J Urol; 2006 Dec; 176(6 Pt 1):2690-5. PubMed ID: 17085197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of bladder cancer.
    Nseyo UO; Lamm DL
    Semin Surg Oncol; 1997; 13(5):342-9. PubMed ID: 9259090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
    Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
    Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and new strategies in immunotherapy for superficial bladder cancer.
    Perabo FG; Müller SC
    Urology; 2004 Sep; 64(3):409-21. PubMed ID: 15351555
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
    Lamm DL; DeHaven JI; Riggs DR; Ebert RF
    J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer.
    Wishahi MM; Ismail IM; Ruebben H; Otto T
    J Urol; 1995 Mar; 153(3 Pt 2):926-8. PubMed ID: 7853576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy.
    Riggs DR; Tarry WF; DeHaven JI; Sosnowski J; Lamm DL
    J Urol; 1992 Jan; 147(1):212-4. PubMed ID: 1729535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Unconventional therapeutic methods in superficial bladder cancer].
    Kälble T; Otto T
    Urologe A; 1994 Nov; 33(6):553-6. PubMed ID: 7817456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder.
    Jurincic-Winkler CD; Gallati H; Alvarez-Mon M; Sippel J; Carballido J; Klippel KF
    Eur Urol; 1995; 28(4):334-9. PubMed ID: 8575503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for superficial bladder cancer. A developmental and clinical overview.
    Morales A; Nickel JC
    Urol Clin North Am; 1992 Aug; 19(3):549-56. PubMed ID: 1378982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of superficial bladder cancer.
    Nseyo UO; Lamm DL
    Semin Oncol; 1996 Oct; 23(5):598-604. PubMed ID: 8893870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment of superficial bladder cancer: an update.
    Crawford ED
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):1-9. PubMed ID: 8727804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keyhole limpet hemocyanin: an effective adjunct against melanoma in vivo.
    Rizvi I; Riggs DR; Jackson BJ; McFadden DW
    Am J Surg; 2007 Nov; 194(5):628-32. PubMed ID: 17936425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.
    Jurincic-Winkler CD; von der Kammer H; Beuth J; Scheit KH; Klippel KF
    Anticancer Res; 1996; 16(4A):2105-10. PubMed ID: 8712751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.